Chiesi, Global

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Veröffentlicht: 07.08.2025 um 18:07 Uhr, prnewswire.co.uk

Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. Israel New York United States of America Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-variation-submission-by-european-medicines-agency-for-pegunigalsidase-alfa-302325605.html

en | boerse | 67948664 |